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Abstract
Background: The pharmacokinetics of extracellular solutes is determined by the blood-tissue
exchange kinetics and the volume of distribution in the interstitial space in the different organs. This
information can be used to develop a general physiologically based pharmacokinetic (PBPK) model
applicable to most extracellular solutes.
Methods: The human pharmacokinetic literature was surveyed to tabulate the steady state and
equilibrium volume of distribution of the solutes mannitol, EDTA, morphine-6-glucuronide,
morphine-3-glucuronide, inulin and β-lactam antibiotics with a range of protein binding (amoxicillin,
piperacillin, cefatrizine, ceforanide, flucloxacillin, dicloxacillin). A PBPK data set was developed for
extracellular solutes based on the literature for interstitial organ volumes. The program PKQuest
was used to generate the PBPK model predictions. The pharmacokinetics of the protein (albumin)
bound β-lactam antibiotics were characterized by two parameters: 1) the free fraction of the solute
in plasma; 2) the interstitial albumin concentration. A new approach to estimating the capillary
permeability is described, based on the pharmacokinetics of the highly protein bound antibiotics.
Results: About 42% of the total body water is extracellular. There is a large variation in the organ
distribution of this water – varying from about 13% of total tissue water for skeletal muscle, up to
70% for skin and connective tissue. The weakly bound antibiotics have flow limited capillary-tissue
exchange kinetics. The highly protein bound antibiotics have a significant capillary permeability
limitation. The experimental pharmacokinetics of the 11 solutes is well described using the new
PBPK data set and PKQuest.
Conclusions: Only one adjustable parameter (systemic clearance) is required to completely
characterize the PBPK for these extracellular solutes. Knowledge of just this systemic clearance
allows one to predict the complete time course of the absolute drug concentrations in the major
organs. PKQuest is freely available http://www.pkquest.com.
Background
The distribution of most hydrophilic solutes (e.g. β-
lactam antibiotics) is limited to the extracellular space
because of their cell membrane impermeability. Thus, the
pharmacokinetics of this large class of compounds is
determined primarily by the volume of distribution and
the kinetics of exchange with the interstitial space. Given
the general importance of this class of drugs, there has
been surprisingly little analysis of the pharmacokinetics of
the interstitial space in humans. The 1959 review article
by Edelman et. al. [1] remains the standard reference on
the extracellular space. In addition, there are two extensive
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reviews of the structure and function of the interstitial
space [2,3].
An accurate pharmacokinetic description of the interstitial
space is essential for the development of a physiologically
based pharmacokinetic model (PBPK) for extracellular
solutes. Although PBPK models have been used exten-
sively to describe human pharmacokinetics, nearly all of
these studies have involved solutes that have intracellular
distributions, and, thus, do not require detailed modeling
of the interstitial space. One exception is the recent appli-
cation of PKQuest to the extracellular solutes inulin and
the beta-lactam antibiotics [4]. PKQuest is a new PBPK
program that has been applied to the human pharmacok-
inetics of a large number of solutes [4–8]. Although the
agreement between the PKQuest PBPK model predictions
and the experimental data for these extracellular solutes
was satisfactory, subsequent application of PKQuest to
other extracellular solutes demonstrated that there was a
small, but systematic, error in the PKQuest predictions.
This error is the stimulus for this more in depth analysis
of interstitial pharmacokinetics.
Probably the most detailed application of a PBPK model
to an extracellular solute is the study of Tsuji et. al. [9] of
the pharmacokinetics of cefazolin in the rat. In this inves-
tigation, nearly every PBPK parameter required by the
model was directly measured, including organ blood
flows and weights, renal and hepatic clearance and the
time dependence of cefazolin concentration in the differ-
ent organs. Tsuji et. al. [9] estimated interstitial volumes
from measurements of the steady state inulin tissue con-
centrations. The interstitial volumes in the original
PKQuest PBPK model were based on these inulin volumes
of Tsuji et. al. [9] scaled to give the correct total volume in
humans. As will be shown below, inulin is not a good sol-
ute to use to measure interstitial volume and this probably
contributed to the error in the earlier PKQuest PBPK
predictions.
Methods
All the experimental data were obtained from earlier pub-
lications. In most cases, the published data represented
the average of the experimental measurements in a
number of subjects and it was assumed that it represented
one "average" subject. In a few cases (indicated by a N = 1
in Table), data for a single subject were published and
used in the calculations. The program UN-SCAN-IT (Silk
Scientific Corporation) was used to read the data from the
published figures. Most of the figures shown in this paper
are direct copies (in jpeg format) of standard PKQuest
output.
Measurement of steady state volume of distribution (Vss)
To ensure that a consistent calculation of Vss was used, all
the values of Vss were recalculated by applying PKQuest
[8] to the published venous concentration data. In this
calculation, deconvolution of the intravenous input is
used to find the 2 or 3 exponential unit dose bolus
response function r(t):
The expression for Vss is then found from the area under
the curve (AUC) and mean residence time (MRT) for this
r(t) (for unit dose):
Measurement of equilibrium volume of distribution (Veq)
The direct approach to the determination of Veq is to give
a constant IV infusion for a period long enough to estab-
lish a steady state plasma concentration (Ceq). For solutes
in which the systemic clearance results only from renal
clearance, the peripheral (tissue) and central concentra-
tions must be in equilibrium at this steady state and Veq is
defined by:
(3)   Veq = Atot / Ceq
where Atot is the total amount of solute present. For the
special case where there is no metabolism and renal clear-
ance in the only excretion route, Atot can be determined by
quantitative urine collection after stopping the infusion. If
the clearance is from just the central compartment (e.g.
renal excretion) Veq (also referred to as Vdrug) is equal to Vss
[10].
The value of Veq can also be estimated for subjects in renal
failure that have a very low rate of renal clearance. As
shown in Appendix I, for the case where the clearance is
very small compared to the rate of exchange between com-
partments, Veq is approximately equal to Vdext (using the
notation of Wagner [11]):
(4)   Veq  Vdext = D / Bβ
where Bβ is the coefficient of the slow, terminal exponen-
tial term of the bolus response function (eq. (1)) and D is
the bolus dose. The value of Bβ was determined using the
deconvolution feature in PKQuest to find the 2-exponen-
tial response function.
PBPK model for extracellular solutes
A new PBPK model was developed that was consistent
with the experimental data in Tables 1,2,3,4,5. Table 6
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summarizes the new set of PBPK parameters for the
"standardhuman" with a total weight of 70 Kg and a 20%
fat content. The parameters are scaled for different body
weight and fat content [7]. The major difference between
this parameter set and that used previously [7] is the dis-
tribution of the extracellular water (ecf_water) among the
different organs. The column labeled ecf_fract is the frac-
tion of the extravascular organ water that is extracellular-
i.e. interstitial. The "adipose" ecf_fract is 1 because it is
assumed that all adipose tissue water is extracellular and
the cells are pure lipid. The brain ecf_fract is zero because
the blood brain barrier will prevent the distribution into
Table 1: Steady-state Volume of Distribution relative to body weight (VSS) and total body water (VSSW) for selected solutes.
Solute Reference Fraction Bound VSS (liters/Kg) VSSW (liters/liter) Comments
2-expon 3-expon
Mannitol [58] ≈ 0 .28 .48 N = 7, 28 years, 70.9 Kg, 178 cm.
EDTA ≈ 0 .265 .45
Mannitol [57] ≈ 0 .33 .33 .56 N = 1, 71.6 Kg, 172 cm.
amoxicillin [62] .17 – .23 .262 .275 .44 N = 9, 66.4 Kg
[61] .267 .253 .45 N = 9, 74.7 Kg, 180 cm
morphine-6-glucuronide [59] 0–.1 .247 .245 .42 N = 20, 74.2 Kg
[42] .30 .40 .50 N = 10, 71 Kg
morphine-3-glucuronide [60] .275 .273 .47 N = 3, Dose/Kg
inulin [37] ≈ 0 .133 .131 .22 N = 1, 87.3 Kg, 173 cm
[39] ≈ 0 .131 .136 .23 N = 1 77.1 Kg 186 cm
[40] ≈ 0 .20 .277 .34 N = 27 Non-linear.
Table 2: Equilibrium Volume of Distribution in Humans relative to body weight (VEQ) for selected solutes.
Solute Reference Fast time constant 
(minutes)
Slow time constant 
(minutes)
VEQ (liters/Kg) Comments
Amoxicillin [46] 9.8 909 0.26 N = 4, 53 Kg, 45 years Renal failure: 
Clearance < 10 ml/min/1.73 m2
Morphine-6-glucuronide [47] 23 2083 0.24 N = 6, 73.7 Kg, 48.7 years Renal 
Failure: Ave. clearance = 10 ml/min
Inulin [44] NA NA 0.15 N = 3, Constant infusion. Normal 
Males, ages 21–29.
Sucrose [45] NA NA 0.159 N = 3, Constant infusion.
Inulin NA NA 0.162
Table 3: Steady state volume of distribution (VSS) and interstitial volume (VI) relative to body weight for β-lactam antibiotics as a 
function of degree of protein binding.
Solute Reference Fraction Bound VSS (liters/Kg) VI (liters/Kg)
amoxicillin [62] .17–.23 .26 .22
[61] .267 .23
piperacillin [30] .48 .23 .19
cefatrizine [31] .62 .194 .155
ceforanide [32] .82 .161 .12
dicloxacilllin [63] .97 .091 .053
amoxicillin [29] .17–.23 .33 .29
flucloxacillin .93 .15 .11BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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the interstitial space of any of the test solutes used in Table
1. The term "solid" refers to the non-fat, organ solids It is
assumed that the entire animal's fat is in the single "lipid"
organ and that this organ is 80% fat. This is a major over-
simplification since adipose blood flow may show large
variations in different adipose tissues [12] and two differ-
ent "fat" compartments have been used in some PBPK
models [13]. An attempt has been made to minimize the
number of adjustable parameters and a single fat com-
partment has provided satisfactory fits to the solutes pre-
viously investigated with PKQuest, including the highly
fat soluble volatile anesthetics [5]. "Portal" refers to the
organs drained by the portal vein (stomach, small and
large intestine, pancreas and spleen). "Bone" refers to the
inert solid component of bone that has no volume of dis-
tribution or blood flow. The blood flow and water com-
ponent of the skeleton is distributed among the rest of the
organs.
The organ weights in Table 6 are close to the values in the
Report on the Task Group on Reference Man [12]. The
"skin" is the sum of the weight of the dermis and epider-
mis. The organ "other" represents primarily the loose con-
nective tissue and the organ "tendon" represents the
denser connective tissue components. The total body
water is 41.84 liters, in agreement with the results of
Chumlea et. al. [14]. It is assumed in Table 6 that the
"blood" volume includes the intra-organ blood volume,
so that the organ parameters refer to the extravascular
composition.
Although the blood flows to the different organs in Table
6 are in general agreement with the "proposed reference"
values of Williams and Leggett [15], they have been fine-
tuned in order to optimize the PBPK model predictions
for selected solutes. The resting muscle blood flow was
adjusted to a value of 2.25 ml/min/100 g (0.0225 L/Kg/
min) to fit the D2O data of Schloerb et. al. [16] as
described previously [6]. This value for muscle blood flow
is similar to the recent measurements in man of resting
muscle blood flow of 2.3 [17] and 3.12 ml/min/100 gm
[Ruotsalainen, #239] using [15O]H2O PET scans and of
2.5 ml/min/100 gm [18] using plethysmographic meas-
urements of calf blood flow. This value is somewhat
higher then 133Xe measurements, which vary from 1.4 to
1.9 ml/min/100 gm [19]. Similarly, the adipose blood
flow in Table 6 was adjusted [5] to a value of 4.4 ml/min/
100 gm to fit the enflurane data of Munson et. al. [20].
This value is close to the recent human [15O] H2O meas-
urements of subcutaneous abdominal (4.8 ml/min/100
gm), visceral (5.9) and perirenal (4.9) fat blood flow [21].
The "tendon" (e.g. connective tissue) blood flow is poorly
characterized and has a large variation. The value of 1 ml/
100 gm/min is representative of direct measurements of
tendon blood flow using microspheres [22,23]. The total
cardiac output of 5.62 L/min is close to the value of 5.82
L/min in normal young men reported by Grimby et. al.
[24].
The volume of distribution in the different organs for sol-
utes that bind to albumin is characterized by the parame-
ter KA
i, the ratio of the albumin concentration in the EDTA
interstitial space to the plasma albumin concentration for
organ i (see Appendix, II and III). The PBPK values of KA
i
for the different organs are listed in Table 6. In the analysis
of the pharmacokinetics of the protein bound β-lactam
antibiotics, an average value of KA (see eq. (10)) for the
entire human is estimated. This corresponds to the organ-
weighted sum:
where ecfi is the interstitial volume of organ i. The PBPK
organ weighted values are listed in the last column of
Table 6, and correspond to an average value of KA of 4.94/
17.45 = 0.28. This is identical to the value that was esti-
mated using the β-lactam antibiotics (see fig. 15).
As described previously [4], capillary permeability limited
solutes are characterized by the organ parameter fclear [i],
the fraction of solute that equilibrates with the tissue in
one pass through the capillary. The fclear of organ i is
related to the capillary permeability-surface area product
(PSi) by the relation:
(6)   fclear [i] = 1 - exp (-fPPSi / Fi)
where fP is the fraction free in the plasma and Fi is the
organ plasma volume flow (liters/min/Kg) [7]. The
parameter fclear ranges from 0 (impermeable capillary) to
1 (flow limited). In PKQuest, the default procedure is to
input just one parameter, the fclear [muscle], and the per-
meability of all the other organs are then automatically
determined using the default values of PSi/PSmuscle pro-
grammed into PKQuest. This accounts for the other phys-
iological factors that determine fclear (organ plasma flow
and plasma protein binding). The following set of default
PS values are assumed: liver, kidney and portal organs are
flow limited, heart and lung have a PS 50 times that of
skeletal muscle, brain has a PS = 0 for solutes that have
fclear [muscle]<1 due to the blood brain barrier, and the
rest of the organs have a PS equal to that of muscle [25].
As can be seen from eq. (6), solutes that have a high
intrinsic capillary permeability (PS) can have a functional
capillary permeability limitation (fclear < 1) if there is a
high degree of plasma protein binding (i.e. fP is small).
This dependence of fclear on protein binding is applied
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Table 4: Interstitial volume (VI) – fraction of total extravascular water
Species Solute Reference Organ VI Comments
Rat EDTA [35,64,65] sk. mus. .081–091 Renal ligature-sampled 30 minutes after 
death.
skin .55–.73
tendon .83
intestine .28–.32
[66] sk. mus .12 Renal ligature-samples from live rat.
skin .63
[67]1 sk. mus. .075 Constant infusion. Measured time course of 
tissue uptake.
skin .52
intestine .15–.25 Muscle, stomach and intestine equilibrated in 
<40 minutes.
stomach .23
adipose .49
liver .34
lung .2
brain ≈ 0
[50] skin .61 Renal ligature – divided skin into dermis and 
sub-cutaneous samples.
dermis .67
subcutis .51
[68]1 sk. mus .15 Constant infusion. Volume increased with 
time for skin and colon. Range indicates 
volume at 60 to 120 minutes
skin .44–.63
sm. intestine .29
colon .3–.41
adipose 1.0
Sulfate [69]1 skin .65 Nephrectomized
muscle .26
Mannitol skin .66
muscle .26
Sulfate [70]1,2 muscle .12 Nephrectomized
Inulin [9] sk. mus. .12 Constant infusion.
skin .3
intestine .12
liver .2
lung .27
[71]1 sk. mus. .1 Constant infusion. Tissue uptake 
corresponds to capillary PS ≈ 0.6 ml/min/100 
gm
Rabbit EDTA [72] sk. mus .077 Renal ligature.
skin .42
EDTA [73]1,2 sk. mus. .10 Renal ligature. Measured time course of 
tissue uptake.
heart .25
Sucrose sk. mus. .11 Equilibrated in < 30 minutes.
heart .25
Inulin sk. mus. .1
heart .24
[74] sk. mus. .09 Renal ligature. Determined time constant T≈ 
9 min.
heart .28 T ≈ 1 min.
intestine .2 T ≈ 1.5 min
ear .5 T ≈ 12 min
Cat EDTA [75] sk. mus. .13 Renal ligature.
skin .88
Dog EDTA [76] sk. mus. .16 Renal ligature.
skin .78BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Sulfate [70]1,2 muscle .20 Constant infusion. Equilibration time <30 
minutes.
Sucrose [49]1 sk. mus. .23 Constant infusion. Cannulated prepopliteal 
lymphatic and measured lymph sucrose
skin .53
tendon .67
Thiosulfate [51]2 muscle .13 Renal ligature. Equilibration time < 180 min.
skin .77 Equilibration time < 180 min
tendon .75 Equilibration time ≥ 360 min.
Inulin muscle .1 Equilibration time < 180 min.
skin .48 Equilibration time < 180 min
tendon .26 Equilibration time ≥ 360 min.
Man Inulin1,2 [77] sk. mus. .08–.11 Bolus plus constant infusion. Tissue biopsy 
after 20 – 120 minutes.
1Assumed total organ water (ml/100 gm) of: skeletal muscle, 75; heart, 78; skin, 60; subcutaneous tendon/ear, 60; stomach, 75; intestine, 73; 
adipose, 18.3; liver, 70; lung, 79 [35,78]. 2Assumed plasma volume (ml/100 gm) of: skeletal muscle, 0.4; heart muscle, 2.0; skin 0.6 [64,78].
Table 5: Interstitial albumin volume as fraction of interstitial EDTA volume (VI
A/VI
E); the interstitial albumin concentration relative to 
plasma albumin (CI/CP); and the product KA = (VI
A/VI
E)(CI/CP).
Species Reference Organ CI/CP VI
A/VI
E KA Comments
Rat [64] sk. mus. 0.8 0.73 0.58 Constant infusion of I125 rat 
serum albumin. Wick tissue 
albumin
skin 0.69 0.6 0.4
tendon 0.61 0.45 0.27
[50] skin-dermis 0.72 0.44 0.32
skin-subcut 0.72 0.57 0.41
Rabbit [79] sk. mus. 0.76 0.53 0.4 Lymph albumin
skin. 0.49 0.47 0.23
Table 6: Spreadsheat description of PBPK parameters for the 70 Kg, 20% fat "standardhuman".
Organ Weight 
(Kg)
Lipid 
Fraction
Solid 
Fraction
Solid 
(Kg)
ecf 
Fraction
water 
(L)
water /Kg ecf 
water(L)
flow (L/Kg) flow (L/min) Ka Ka*ecf
Blood 5.5 0 0.18 0.99 0.595 4.51 0.82 2.68345
liver 1.8 0 0.3 0.54 0.23 1.26 0.7 0.2898 0.25 0.45 0.5 0.1449
portal 1.5 0 0.22 0.33 0.3 1.17 0.78 0.351 0.75 1.125 0.35 0.1228
muscle 26 0 0.22 5.72 0.15 20.28 0.78 3.042 0.0225 0.585 0.5 1.521
kidney 0.31 0 0.2 0.062 0.165 0.248 0.8 0.04092 4 1.24 0.35 0.0143
brain 1.4 0 0.2 0.28 0 1.12 0.8 0 0.56 0.784 0.1 0
heart 0.33 0 0.2 0.066 0.25 0.264 0.8 0.066 0.8 0.264 0.5 0.033
lung 0.536 0 0.2 0.107 0.2 0.428 0.8 0.08576 10.482 5.6184 0.35 0.03
skin 2.6 0 0.3 0.78 0.6 1.82 0.7 1.092 0.1 0.26 0.25 0.273
tendon 3 0 0.15 0.45 1 2.55 0.85 2.55 0.01 0.03 0.25 0.6375
other 5.524 0 0.15 0.828 0.8 4.695 0.85 3.75632 0.02 0.1104 0.25 0.9390
bone 4014 0 . 50 00 0 0 0
adipose 17.5 0.8 0 0 1 3.5 0.2 3.5 0.044 0.77 0.35 1.225
Total 70 0.2 14.15 41.84 17.4572 5.6184 4.9406
Table 4: Interstitial volume (VI) – fraction of total extravascular water (Continued)BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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below in the application of PKQuest to a series of β-
lactam antibiotics with varying protein binding.
All the PBPK calculations use PKQuest [7]. A small modi-
fication of the earlier version of the software is required to
account for the new situation where the interstitial vol-
ume of distribution of protein is less than that of EDTA
(see Appendix, III). Four parameters characterize the inter-
stitial volume of distribution for each organ i: 1) ecf [i] –
the interstitial volume of EDTA as the fraction of the total
organ water; 2) mecf – a multiplicative constant that
scales all the values of ecf [i]; 3) frecf [i] – interstitial vol-
ume of the solute relative to that of EDTA; and 4) (for sol-
utes that are protein bound) cProt [i], which is the
PKQuest parameter corresponding to KA
i. Standard values
of ecf (Table 6), frecf (=1) and cProt (KA
i, Table 6) are pre-
programmed in PKQuest. The only parameter that needs
to be input by the user is mecf. Setting mecf =1 indicates
that the solute distributes in the standard ecf space. (The
default value of mecf is -1, indicating that the solutes dis-
tributes in all the tissue (interstitial and intracellular)
space.) The complete PBPK pharmacokinetics of each sol-
ute is characterized by a short Maple worksheet that lists
the parameters that differ from the default "standardhu-
man" parameters. The complete worksheets for the 11 sol-
utes are included in the additional file
"PKQuest_worksheets.doc". For all of the solutes investi-
gated in this paper, the kidney is the major excretion path-
way. The renal clearance is described two different ways in
these worksheets. If the clearance is close to the free
plasma glomerular clearance, than the parameter "rclr"
(glomerular filtration rate) is used. For solutes that are
cleared both by glomerular filtration and tubular secre-
tion, the single parameter Tclr [kidney] is used (the rate of
renal clearance of the free (unbound) plasma solute).
PKQuest is used to find the values of the adjustable
parameters that provide the best fit to the experimental
data by minimizing the error function:
The parameter "noise" adds a weighting factor that
reduces the contribution of the low concentration data
points. The default value for noise is 10% of the average
concentration. (Optionally, PKQuest allows the choice of
a mean square error term, and an arbitrary "noise" can be
input).
Correction for antecubital vein sampling
Ideally, one would like to be able to sample arterial blood
for the calculations of steady state volume of distribution
and for PBPK model fitting. However, all of the data used
in this paper was obtained by measuring the plasma con-
centrations in antecubital venous blood which differs
from the arterial concentration due to the exchange with
the tissues drained by the antecubital vein. A new feature
has been added to PKQuest that allows one to directly cor-
rect for this effect in the PBPK model fitting. The tissue/
flow distribution supplying the antecubital vein was
established by applying PKQuest to the experimental data
for a number of solutes for which simultaneous arterial
and antecubital vein concentrations are available (Levitt,
in preparation). This analysis indicated that antecubital
vein blood represents approximately 10% muscle, 20%
skin, 5% "other", 5% adipose and the rest (60%) A-V
anastomoses. In PKQuest, specifying "arm" as the sample
site outputs the antecubital vein concentration and uses
this concentration to optimize the PBPK parameters using
the PKQuest minimization routines [7]. This allows one
to use antecubital vein blood samples when adjusting
PBPK parameters for an arbitrary uncharacterized solute.
Figure 1 shows the results of this analysis for two of the
extracellular solutes (DTPA and inulin) that were investi-
gated to determine the organ composition of antecubital
blood. The squares show the experimental measurements
of the 99Tcm-DTPA (left column) and inulin (right col-
umn) sampled simultaneously from the artery (black)
and antecubital vein (red) after a bolus venous input. The
lines show the PBPK model fits for the arterial (black) and
antecubital vein (red) concentrations. The difference
between the arterial and antecubital vein concentrations
become negligible after the first 5 to 10 minutes because
the antecubital vein blood is supplied primarily by high
blood flow skin and A-V anastomoses in the hand [26].
For the solutes investigated in this paper, the differences
between arterial and antecubital vein concentration are
very small (e.g. see fig. 2) and this correction is of minor
importance. It is fortunate that this is the case. Otherwise,
one could not use antecubital vein data for PBPK mode-
ling. Unless otherwise stated, all the PBPK model data
shown in the figures in this paper correspond to antecu-
bital vein blood.
Chiou [27] has emphasized that the measurement of the
steady state volume of distribution (Vss) using eq. 2 is
dependent on the sampling site and has shown that the
value of Vss determined using antecubital vein blood will
be greater than the true value of Vss using arterial blood.
This effect can be quantitated for the extracellular solutes
investigated in this paper using the experimental or PBPK
model data shown in figure 1. Using this data, the value
of Vss for the antecubital sampling site is from 4% (PBPK
model) to 10% (experimental data) greater than the true
arterial Vss. The values of Vss reported below are for the
antecubital vein data. A small correction will be applied
when these results are used to estimate the true extracellu-
lar volumes.
() 7 Error Function
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Arterial (black) and antecubital vein (red) concentrations of 99Tcm-DTPA (right column) and inulin (left column) after a bolus  injection using the experimental data (squares) of Cousins et. al. [56] Figure 1
Arterial (black) and antecubital vein (red) concentrations of 99Tcm-DTPA (right column) and inulin (left column) after a bolus 
injection using the experimental data (squares) of Cousins et. al. [56]. The solid lines indicate the PBPK model predictions for 
the arterial (black) and antecubital vein (red) concentrations. The top row shows a plot of the absolute concentration and the 
bottom row is a semi-log plot of the same data. The PBPK parameters for DTPA were identical to those used for EDTA (see 
fig. 3).
DTPA InulinBMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK model predictions and experimental data for mannitol plotted using linear (left) or semi-log (right) Figure 2
Comparison of PBPK model predictions and experimental data for mannitol plotted using linear (left) or semi-log (right). The 
predictions for the experimental data of Laker et. al. [57] (top) and Elia et. al. [58] (bottom) are shown using the parameters in 
Table 6. Both the model arterial (black) and antecubital vein (red) concentration curves are shown.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Results
Experimental measurements of whole animal and 
individual organ volumes of distribution for extracellular 
solutes
Table 1 summarizes the experimental measurements in
humans of the steady state volume of distribution (Vss) for
mannitol, EDTA, amoxicillin, morphine-3-glucuronide,
morphine-6-glucuronide and inulin. The volume of distri-
bution is expressed in terms of total body weight (Vss, lit-
ers/Kg) and total body water (Vssw, liters/liters). The latter
calculation was based on an assumption of a value of 41
liters of water for the standard 70 Kg man with 20% body
fat [14]. The total body water was adjusted for body fat
estimates if information was available. Table 2 lists the
values of the equilibrium volume of distribution (Veq) for
amoxicillin, morphine-6-glucuronide, sucrose and inulin
(see Methods). Table 3 lists the Vss and the interstitial vol-
ume (VI) for a series of β-lactam antibiotics with varying
amounts of plasma protein binding. VI was estimated by
subtracting a plasma water volume of 2.68 liters/70 Kg
from Vss. The human serum protein binding values used
in Tables 1,2,3 were from the following references: amox-
icillin [28,29]; piperacillin [30]; cefatrizine [31]; cefora-
nide [32]; dicloxacillin [33]; flucloxacillin [29,33];
morphine-3-glucuronide and morphine-6-glucoronide
[34]. Table 4 lists the interstitial volume as a fraction of
total extravascular organ water for selected solutes in rats,
rabbits, cats, dogs and man.
The solutes listed in Table 4 have a rapid, possibly flow
limited, exchange between the blood and interstitial space
so that the interstitial space equilibrates with the blood. In
contrast, albumin has a very slow rate of tissue-plasma
exchange with a time constant of about 100 hours in the
rat [35]. Because of this low permeability, the steady state
interstitial albumin concentration in a given tissue (CI) is
less than the plasma concentration and is determined by
the balance between the rate of trans-capillary exchange
and the rate of removal by lymph flow [36]. The standard
procedure used to measure this concentration CI is to sam-
ple the lymph draining that tissue, or to use the wick
method to sample the free tissue albumin. The interstitial
albumin volume of distribution VI
A for that tissue is then
defined by:
The fourth column in Table 5 lists the steady-state albu-
min tissue/plasma concentration ratios (CI/CP) and the
fifth column lists the corresponding ratio VI
A/VI
E (where
VI
E is the interstitial volume of EDTA) for skeletal muscle,
skin and tendon. VI
A is less than VI
E because the interstitial
matrix behaves like a size exclusion gel, restricting the
albumin volume of distribution [3]. This excluded vol-
ume is larger in skin and tendon then in skeletal muscle,
resulting, presumably, from varying concentrations of
collagen and hyaluronan in the different tissues. The sixth
column is the product of these two ratios:
This product for organ i, which will be referred to as KA
i, is
the relevant parameter determining the pharmacokinetics
of albumin bound solutes, such as the β-lactam antibiot-
ics (see Appendix, II).
PBPK model for extracellular solutes
The PKQuest PBPK model [7] was applied to the extracel-
lular solutes using the new set of parameters (Table 6). A
comparison of the model predictions with the experimen-
tal data is shown in figs. 2,3,4,5 for mannitol, EDTA, mor-
phine-6-glucuronide and morphine-3-glucuronide –
solutes with low or negligible protein binding. Since one
of the purposes of this analysis is to find a single, unique
PBPK model applicable to all extracellular solutes, the
identical set of PBPK parameters has been used in all these
figures. The only parameter that was varied for each solute
is the renal clearance, determined using the optimization
feature in PKQuest (see Methods). Figure 2 shows the
PBPK model predictions for both the arterial and antecu-
bital vein concentration (see Methods). It can be seen that
the difference is small. In all other figures, only the
antecubital vein concentration is shown.
All of the solutes shown in figs. 2,3,4,5 have been
assumed to be flow limited. This is clearly not the case for
inulin, which is the prototypical capillary permeability
limited solute. In addition, the interstitial volume of dis-
tribution of inulin (VI) is clearly significantly smaller than
that of EDTA (Table 1). In PKQuest, the parameter mecf
scales the interstitial volume of all non-blood organs by
the same amount. Thus, for inulin, there are 3 adjustable
parameters: 1) the renal clearance ("rclr"); 2) the intersti-
tial volume relative to that for EDTA ("mecf"); and 3) the
capillary permeability for muscle ("fclear [muscle]")
which sets the permeability for all the other organs (see
Methods). The parameter fclear indicates the fraction of
the solute that equilibrates with the tissue in one pass
through the capillary. The flow-limited case corresponds
to an fclear equal to 1. Figure 8 shows the PBPK model
results for four different sets of experimental inulin data.
The values of mecf (= 0.42) and fclear [muscle] (= 0.409,
corresponding to PSmuscle = 0.61 ml/min/100 g, see eq.
(6)) were first determined by optimizing the fit to the data
of Odeh et. al. [37] (top row, fig. 6). A good fit (average
error less than 2%) was obtained with the 3 adjustable
parameters. To test the validity of this result, 3 other sets
of experimental data were fitted, using these identical val-
ues of mecf and fclear [muscle] and only adjusting the
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renal clearance. The result of this procedure are shown in
figure 6 for the experimental data of Orlando et. al. [38]
(second row), Ladegaard-Pedersen et. al. [39] (third row)
and Prescott et. al. [40] (bottom row). The agreement
between the PBPK model and the experimental data is
quite good, except for the long time data of Prescott et. al.
[40]. This discrepancy is expected, since the inulin clear-
ance in the experiments of Prescott et. al. was non-linear,
decreasing by about 50% at low concentrations (long
times). It is not clear why the data in the other three exper-
iments in fig. 6 do not show this marked non-linearity.
Figures 7,8,9,10,11,12 compare the PBPK model predic-
tions with experimental data for the six β-lactam
antibiotics listed in Table 3 (amoxicillin, piperacillin,
cefatrizine, ceforanide, flucloxacillin and dicloxacillin).
The influence of the protein (albumin) binding on the
pharmacokinetics of these solutes is characterized by the
default PKQuest values for KA
i in the different organs
(Table 6, see Appendix, II and III) and the experimental
values for the fraction bound in plasma (fp, Table 1). The
effect of including a capillary permeability limitation was
investigated for these solutes because, as discussed above
(see eq. (6)), one would predict that solutes with a high
amount of protein binding should be capillary permeabil-
ity limited. (All the other parameters were identical to
those used in figs. 2,3,4,5). The addition of a capillary per-
meability limitation provides a significant improvement
Comparison of antecubital PBPK model predictions (line) and experimental data (squares) for EDTA [58] plotted using linear  (left) or semi-log (right) Figure 3
Comparison of antecubital PBPK model predictions (line) and experimental data (squares) for EDTA [58] plotted using linear 
(left) or semi-log (right).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for morphine-6-glucuro- nide for experimental data of Lotsch et. al. [59] (top row) and Penson et. al. [42] (bottom row) Figure 4
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for morphine-6-glucuro-
nide for experimental data of Lotsch et. al. [59] (top row) and Penson et. al. [42] (bottom row).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
Page 13 of 29
(page number not for citation purposes)
in the fit between the PBPK model and the experimental
data for the two antibiotics with the highest degree of
binding, dicloxacillin (97% bound, fig. 12) and flucloxa-
cillin (93% bound, fig. 11). For ceforanide (fig. 10),
which is 82% bound, there is a slight improvement in the
fit with the addition of a small permeability limitation.
The value of the PS product for these three permeability
limited solutes is 11.3 ml/min/100 g (fclear= 0.25) for
dicloxacillin, 7.0 ml/min/100 g (fclear = 0.344) for flu-
cloxacillin and 5 ml/min/100 g (fclear = 0.52) for cefora-
nide. For the other antibiotics (amoxicillin, piperacillin
and cefatrizine) with protein binding of 62% or less, the
addition of a capillary permeability limitation does not
significantly improve the fit. For these flow limited antibi-
otics (amoxicillin, piperacillin, cefatrizine), there is only 1
adjustable parameter – the renal clearance. For the capil-
lary permeability limited solutes (ceforanide, flucloxacil-
lin, dicloxacillin) there are two adjustable parameters, the
renal clearance and fclear [muscle].
This new PBPK parameter set (Table 6) also provided
good fits (not shown) to the other solutes that have been
previously investigated with PKQuest (propranolol [7],
D2O and ethanol [6], anesthetic gases and toluene [5]).
The slightly modified Maple worksheets describing these
solutes are available on the PKQuest web site http://
www.pkquest.com.
Discussion
Volume of distribution of selected extracellular solutes in 
humans
Table 1 summarizes the experimental measurements in
humans of the steady state volume of distribution (Vss) for
mannitol, EDTA, amoxicillin, morphine-3-glucuronide,
morphine-6-glucuronide and inulin. In order to be
included in this table, solutes had to meet the following
criteria: 1) extracellular distribution; 2) low level of
plasma protein binding, 3) no evidence of any unusual
tissue binding or accumulation; 4) major excretory path-
way is renal; 5) linear pharmacokinetics; and 6) published
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for morphine-3-glucuro- nide for experimental data of Penson et. al. [60] Figure 5
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for morphine-3-glucuro-
nide for experimental data of Penson et. al. [60].BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for inulin Figure 6
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for inulin. The parame-
ters rclr, mecf, and fclear [muscle] were adjusted to give the optimal fit to the data of Odeh et. al. [37] (top row). These values 
of mecf and fclear [muscle] were then used to fit the experimental data of Orlando et. al. [38] (second row), Ladegaard-Peder-
sen et. al. [39] (third row) and Prescott et. al. [40] (bottom row), varying only the renal clearance to obtain the best fit.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for amoxicilllin for  experimental data of Sjovall et. al. [61] (top row) and Arancibia et. al. [62] (bottom row) Figure 7
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for amoxicilllin for 
experimental data of Sjovall et. al. [61] (top row) and Arancibia et. al. [62] (bottom row). The flow limited PBPK model is used 
(no capillary permeability limitation).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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data describes the plasma time course in humans in
enough detail that the value of Vss could be recalculated
using PKQuest (see Methods). These 6 conditions are
quite restrictive and most other drug classes do not meet
all of these conditions. For example, although the
aminoglycosides (e.g. gentamicin) satisfy conditions 1, 2,
4 and 5 and 6, they are known to be actively concentrated
in the renal cortex and in several other organs [41]. There
is even a suggestion that inulin, the classic extracellular
solute, may not satisfy condition 5 because of non-linear
renal clearance [40].
There are two ambiguities in this calculation of Vss. First,
as discussed above in the Methods section, the use of
antecubital vein samples should lead to a value of Vss that
is about 5 to 10% greater than the true value. Second, the
calculation of Vss using eq. (2) depends on an accurate
extrapolation of the venous concentration to long times to
determine the integrated mean residence time. Errors in
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for piperacillin from  Lode et. al. [30] Figure 8
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for piperacillin from 
Lode et. al. [30]. The flow limited PBPK model is used (no capillary permeability limitation).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for cefatrizine from Pfef- fer et. al. [31] Figure 9
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for cefatrizine from Pfef-
fer et. al. [31]. The top row is for the flow limited model (fclear = 1) with an average error between PBPK model and experi-
mental data of 5.4%. The addition of a small capillary permeability limitation does not significantly improve the fit (not shown).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for ceforanide from Pfef- fer et. al. [32] Figure 10
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for ceforanide from Pfef-
fer et. al. [32]. The top row is the optimal fit for the case of a capillary permeability limitation (fclear [muscle] = 0.518, PSmuscle 
= 5 ml/min/100 gm, average error = 4.3%). The bottom row is the best fit for the flow limited case (fclear = 1, average error = 
8.6%).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
Page 19 of 29
(page number not for citation purposes)
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for flucloxacillin from  Wise et. al.[29] Figure 11
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for flucloxacillin from 
Wise et. al.[29]. The top row is the optimal fit for the case of a capillary permeability limitation (fclear [muscle] = 0.344, PSmuscle 
= 7.0 ml/min/100 gm, average error = 6.4%). The bottom row is the best fit for the flow limited case (fclear = 1, average error 
= 11%).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for dicloxacillin from  Lofgren et. al. [63] Figure 12
Comparison of PBPK linear (left) or semi-log (right) plots of model predictions and experimental data for dicloxacillin from 
Lofgren et. al. [63]. The top row is the optimal fit for the case of a capillary permeability limitation (fclear [muscle] = 0.25, 
PSmuscle = 11 ml/min/100 gm, average error = 12%. The bottom row is the best fit for the flow limited case (fclear = 1, average 
error = 18%).BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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the long time, low concentration venous concentrations
can produce large errors in the extrapolated MRT. The pro-
cedure used in Table 1 involves using deconvolution to
find a multi-exponential unit bolus response function,
and then integrating this function from 0 to infinity (see
eq. 2). The values of Vss were calculated using either a 2 or
3 (if there were enough experimental data points) expo-
nential function. Some indication of the accuracy of this
extrapolation can be obtained by comparing the results
for the 2 and 3 exponential functions, listed in Table 1.
The calculation with the largest difference between the Vss
calculated for the 2 and 3-exponential function is for the
morphine-6-glucuronide data of Penson et. al. [42]. Fig-
ure 13 compares the semi-log fits for the 2 (black line) and
3-exponential (red line) functions to the experimental
venous data. In the figure on the left, which displays the
two fits over the time of the experimental measurements
(600 minutes), the fits look almost identical. However, as
can be seen in the right figure, which extends the fits out
to 2000 minutes, the 3-exponential fit has a markedly dif-
ferent extrapolation, producing the 33% greater value of
Vss for the 3-exponential fit (Table 1). As this figure illus-
trate, the value of Vss will be underestimated if there is a
compartment with a very long time constant (e.g. 690
minutes for the 3-exponential fit, fig. 1). For each solute
in Table 1, the 2-exponential fit was superior using the
standard statistical tests [43], and this is the value that was
used to determine Vssw (Table 1) and was used in this
paper.
Both of these ambiguities can be avoided if one can meas-
ure the true equilibrium volume of distribution (Veq).
One approach that has been used in humans is to first
establish a steady state concentration using a long, con-
stant IV infusion. The equilibrium volume of distribution
(Veq) is then determined using eq. 3, where Ceq is the
steady state plasma concentration, and Atot is the total
amount of solute in the animal. If the solute is not metab-
olized and the kidney is the only route of excretion, Atot
can be determined by quantitative urine collection after
stopping the infusion. The measurements of Schwartz et.
al. [44] of the Veq of inulin represent the most detailed
investigation of this type in humans (Table 2). Schwartz
et. al. [44] infused inulin for periods up to 30 hours and
Comparison of morphine-6-glucuronide experimental data [42] with venous concentration predicted using either a 2 (black) or  3 (red) exponential bolus response function Figure 13
Comparison of morphine-6-glucuronide experimental data [42] with venous concentration predicted using either a 2 (black) or 
3 (red) exponential bolus response function.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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found that equilibration was at least 95% complete by 5
hours. This indicates that there are no compartments with
significant volumes of distribution with time constants
longer than 300 minutes. There is some evidence that the
renal clearance of inulin is non-linear [40] which, if cor-
rect, could produce an error in the Vss calculation for inu-
lin in Table 1. However, this non-linearity would have no
effect on the Veq calculations in Table 2. Deane et. al. [45]
used this constant infusion approach to compare the Veq
of inulin and sucrose and reported that the sucrose Veq is
slightly smaller than that of inulin (Table 2). This result is
not consistent with the other measurement of Veq or Vss
(Tables 1 and 2), which indicate that solutes of the size of
sucrose should have significantly larger volumes of
distribution than inulin. One explanation for this incon-
sistency is that there is significant extrarenal clearance of
sucrose so that the value of Atot (determine by 24 hour
urine collection) is underestimated.
For animal studies, the most direct measurement of Veq for
solutes with no extrarenal clearance is to nephrectomize
the animal and determine the equilibrium concentration
after a bolus IV injection. Although this is not an option
for humans, a good approximation to this situation can
be obtained in subjects with renal failure and very low
rates of clearance. For this case, Veq can be estimated from
the coefficient of the slow exponential term in the bolus
response function (see Methods). Figure 14 shows the
good agreement between the predicted venous
concentration using a 2-exponential bolus response func-
tion and the experimental data of Arancibia et. al. [46] for
amoxicillin and Hanna et. al. [47] for morphine-6-glu-
curonide. Because of the low clearance rate in these sub-
jects, measurements can be extended for longer times
(720 minutes for morphine-6-glucuronide and 1440
minutes for amoxicillin) then those used in Table 1. The
value of Veq and the time constants for the slow and fast
compartments are listed in Table 2. For both solutes, the
Comparison of experimental data with venous concentration predicted using a 2-exponential bolus response function for  amoxicillin (left) and morphine-6-glucuronide (right) in subjects with renal failure Figure 14
Comparison of experimental data with venous concentration predicted using a 2-exponential bolus response function for 
amoxicillin (left) and morphine-6-glucuronide (right) in subjects with renal failure.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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time constant for the slow compartment is about 100
times longer that that for the fast compartment. The time
constant of the slow compartment (909 and 2083 min-
utes) reflects the slow rate of systemic clearance in these
subjects. If there were a slowly exchanging compartment
that was missed in these subjects, it must have a time con-
stant longer than 900 minutes, which seems unlikely. The
values of the "equilibrium" volume of distribution listed
in Table 2 are consistent with the values of Vss listed in
Table 1 which, as discussed above, should be 5 to 10% too
large because of antecubital vein sampling.
The results in Tables 1 and 2 indicate that the extracellular
volume of distribution is surprisingly large, about 42% of
the total body water. The distribution of this space among
the different organs will be discussed in the next section.
Tables 1 and 2 also show that the volume of distribution
of inulin is about one half the value of the other solutes.
This difference is supported by the results of Ladegaard-
Pedersen and Engell [48] who found that the inulin
volume was, on average, 48% smaller than the EDTA
volume in a series of 22 patients. It is ironic that inulin,
which is usually regarded as the classical, standard, extra-
cellular marker, seems to be a poor representative of the
extracellular space for the typical pharmacokinetic agent.
The reduced volume for inulin is presumably produced by
the "excluded volume" associated with the interstitial
matrix [3], similar to the excluded volume of albumin.
Tissue distribution of interstitial volume (VI)
Table 4 summarizes the measurements in the literature of
the interstitial volumes (VI) of different organs for a series
of extracellular solutes. The value of VI is expressed as the
fraction of the total extravascular organ water. The most
striking aspect of the results in this table is the marked
variation in VI for different tissues – varying from about 10
to 15% of total tissue water for skeletal muscle, to 50 to
70% for skin to 80% for tendon. (The high value of 23%
for VI obtained by Bell et. al. [49] in the dog is probably
associated with the manipulations required to collect the
lymph [50]). The measurements in the dog by Nichols et.
al. [51] in 1953 (Table 4) represent the first detailed inves-
tigation of the tissue distribution of interstitial volume
and form the basis of the current understanding of the
extracellular space. These early measurements of Nichols
et. al. [51] emphasized the important contribution of con-
nective tissue (represented by tendon) to the total intersti-
tial kinetics [51,52]. In general, the more recent results in
Table 4 are in agreement with these earlier measurements.
Volume of distribution of protein bound β-lactam 
antibiotics
The above discussion has assumed that the test solutes
distribute freely in the extracellular blood and tissue water
without any binding so that, at equilibrium, the intersti-
tial and plasma concentrations are equal. This is not true
if there is blood and/or tissue binding. In this case, the
volume of distribution (see eq. (3)) will depend on the
degree of tissue binding relative to plasma binding. For
the general case, the binding in the different tissues will be
unique for each solute, requiring direct tissue binding
measurements. However, for the case where the binding is
linear and is only due to the plasma and tissue albumin,
one can derive (see Appendix, II) the following general
relationship for the ratio of the interstitial volume of
distribution of solute i (VI
i) relative to the interstitial
EDTA volume of distribution (VI
E) as a function of fP
i, the
fraction of solute i that is free in plasma:
The parameter KA is the ratio of the albumin concentra-
tion in the EDTA interstitial space to the plasma albumin
concentration (eq. (9)). The KA in this equation is for the
whole animal and is the weighted average of the KA
i (see
eq. (5)) for the individual organs (see Tables 5 and 6). The
parameter αi is the ratio of the interstitial space for solute
i relative to EDTA in the absence of binding. Since EDTA
and the β-lactam antibiotics are of similar size, αi should
be close to 1. In the limit of no protein binding (fP = 1),
VI
i/VI
E = αi. In the limit of very strong binding (fP = 0), VI
i/
VI
E = KA (the ratio of tissue to plasma albumin).
Plot of VI
i/VI
E versus fp
i for the β-lactam antibiotics listed in  Table 3 Figure 15
Plot of VI
i/VI
E versus fp
i for the β-lactam antibiotics listed in 
Table 3. The red line, which is the least squares linear fit to 
the data, has a slope of 0.83 and intercept of 0.28.
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Table 3 lists the Vss and VI of a series of β-lactam antibiotics
with varying amounts of plasma protein binding. These
antibiotics should satisfy the assumptions required for eq.
(10) since they all have linear kinetics and the protein
binding results primarily from binding to albumin. Figure
15 shows a plot of VI
i/VI
E versus fp
i for these solutes. (The
Vss  for flucloxacillin in Table 3 was scaled for an
amoxicillin value of 0.26). According to eq. (10), the data
points in this plot should fall on a straight line, with a
slope of (αi-KA) and intercept of KA. The line in fig. 15,
which is the least squares fit to the data points, corre-
sponds to a KA of 0.28 and an αi of 1.1. Comparing this
value of KA, which represents a weighted average for the
whole animal (eq, (5)), to the value of KA
i for the individ-
ual organs (Table 5) suggest that organs such as skin, ten-
don and connective tissue dominate the contribution to
the total KA.
PBPK model parameters for extracellular solutes
Based on the physiological data in Tables 1,2,3,4,5, a new
set of PBPK parameters was developed that should pro-
vide a more accurate description of extracellular solutes,
while remaining valid for the other solutes modeled
previously by PKQuest. Table 6 (see Methods) summa-
rizes the new PBPK data set. The comparison of the PBPK
model predictions using this new parameter set with the
experimental data is shown in figures
2,3,4,5,6,7,8,9,10,11,12 for the 11 solutes listed in Tables
1 and 3.
Distributing the extracellular water among the different
organs presents something of a conundrum. If one uses
the data from Table 4 for the organs that are usually
regarded as making up most of the non-fat, non-bone
body weight (blood, muscle, skin, gastrointestinal (por-
tal) and liver), one can only account for about 7.3 liters of
extracellular water, less than half the total value of about
17.3 liters based on the VSS data in Table 1 (extracellular
water equal to 42% of total body water). Since the only
other organs of any significant weight are the adipose and
connective tissue, these organs must represent a large frac-
tion of the total extracellular water. Connective tissue is
very heterogeneous, – consisting of tendons, cartilage,
subcutaneous, etc. It is poorly characterized and values for
its weight, composition, and blood flow represent, at best,
crude estimates. In the classic reference on the
extracellular space, Edelman and Leibman [1] estimated
that the connective tissue had a mass of 6 Kg and was 70%
water (4.2 liters). The fraction of adipose tissue that is
extracellular water varies for different locations. One com-
ponent of the adipose tissue is the subcutaneous compo-
nent of skin ("subcutis"). In the measurements of Reed et.
al. [50] in the rat, subcutis is about 70% water, of which
about 51% is extracellular (see Table 4). Adipose tissue in
other locations can have much smaller extracellular
components. If one assumes that, on average, adipose tis-
sues is 70% lipid and 30% water, then, for the standard
human (70 Kg, 20% fat) adipose tissue will contain 6 lit-
ers of water.
Based on the above estimates, adipose and connective tis-
sue contain about 10.2 liters of water. For the PBPK model
in Table 6, it is assumed that most of this water is extracel-
lular and it is distributed between "adipose" tissue and
two connective tissue organs: "tendons" with a relatively
low water fraction and low blood flow, and "other" with
a higher water fraction and higher blood flow. The total
extracellular volume for this PBPK data set is 17.45 liters,
or 42% of the total water (Table 6).
As described above (see eq. (10), the interstitial volume of
distribution of the β-lactam antibiotics depends on the
parameter KA, the ratio of the albumin concentration in
the EDTA interstitial space to the plasma albumin concen-
tration. This value represents the sum over all the different
organs. Each individual organ i is characterized by a value
of KA
i. The assumed PBPK values of KA
i for the different
organs are also listed in Table 6. It is assumed that the
organs "skin" and "other" have a smaller value of KA
i then
the other organs, consistent with the experimental data in
Table 5. The organ-weighted total value of KA is 0.28 (see
Table 6 and eq. (5)), identical to the value obtained by fit-
ting the data in Table 3 (fig. 15).
Capillary Permeability Limitation
Although nearly all PBPK models assume that the blood-
tissue exchange for solutes such as EDTA or the β-lactam
antibiotics is "flow-limited" (i.e., infinite capillary perme-
ability), there is only indirect evidence to support this
assumption. The standard approach that is used to exper-
imentally determine the capillary permeability-surface
area product (PS) is the organ perfused early extraction
(E0) method [25]. For an ideal, homogeneous organ, E0 is
equal to the PKQuest parameter "fclear" (see, eq. (6)), the
fraction of solute that equilibrates with the tissue in one
pass through the capillary [4]. A flow-limited solute has
an fclear of 1. As shown in eq. (6), fclear is a function of 3
different physiological parameters: 1) the capillary
permeability-surface area product (PS); 2) the organ
plasma flow (F); and 3) the fraction of the solute that is
free in the plasma (fP). The standard reference value for
the PS of EDTA in skeletal muscle, skin and subcutaneous
tissue is about 5 ml/min/100 g [25]. Substituting this
value for PS in eq. (6) and using the resting muscle blood
flow of 2.25 ml/min/100 gm (Table 6) yields an fclear of
0.89. That is, there is 89% equilibration of EDTA in one
pass through the capillary. Since it is difficult to experi-
mentally distinguish an fclear of 0.89 from an fclear of 1
– this result is consistent with the flow limited assump-
tion for EDTA.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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There are several uncertainties in this estimate of fclear. To
accurately measure PS with the E0 method it is necessary
to use relatively high rates of perfused organ flows so that
E0 (and fclear) are much less than 1. In addition, the E0
method tends to underestimate the true value of fclear
because of factors such as back diffusion and capillary het-
erogeneity [53,54]. This underestimate is greater for sol-
utes with relatively high permeability, such as EDTA. The
two most recent measurements of the skeletal muscle PS
of EDTA are 5.0 ml/min/100 g in the cat [55] and 12.9 in
rat [54]. Both of these studies have emphasized the impor-
tance of using very high blood flows to eliminate the
effects of heterogeneity and back diffusion. However, the
PS at these high flows (at least 10 times resting flows) may
not be relevant to the value of PS at the resting muscle
blood flows that are required for the human pharmacoki-
netic studies. In particular, one would expect that the PS
product would be greater at the high flows because the
value of S (capillary surface area) would be increased as a
result of recruitment of additional capillaries. In addition,
the capillaries that are recruited at high flows may not be
representative of the low flow capillaries.
The use of the β-lactam antibiotics provides a new
approach to the measurement of capillary permeability at
resting blood flows [4]. Since the factor fP multiplies the
exponential term in eq. (6), a high protein binding (small
fP) is kinetically equivalent to increasing the blood flow.
For example, flucloxacillin, which is 93% bound, has an
fP of 0.07 and a corresponding fclear of 0.15 for a PS of 5
ml/min/100 g and resting muscle blood flow. That is, at
resting blood flows only 15% of the plasma flucloxacillin
will equilibrate with the tissue in one pass – a large
capillary permeability limitation. The use of these protein
bound antibiotics allows one to directly measure the cap-
illary permeability at low flows without the uncertainty
introduced by heterogeneity and back diffusion.
The approach used in this paper to establish if the antibi-
otics are flow limited is to determine whether the agree-
ment between the PBPK model and the experimental data
was improved by inputting an fclear [muscle] that is less
than 1, i.e. a capillary permeability limitation. This is an
indirect approach because one would expect that the fit
should improve just because another adjustable
parameter is introduced. Despite this proviso, there is lit-
tle doubt that the two antibiotics with the highest degree
of protein binding, dicloxacillin (fig. 14, fP = 0.03; fclear =
0.25) and flucloxacillin (fig. 13, fP = 0.07; fclear = 0.344)
have a significant capillary permeability limitation. Com-
paring the PBPK model output for the flow limited and
permeability limited conditions in figs. 13 and 14, it can
be seen that the primary effect of the permeability limita-
tion is at early times, increasing the initial peak in the
plasma concentration. For ceforanide, the third highest
binding antibiotic in Table 3 (fP = 0.18, fig. 12), there is a
slight improvement in the fit using a fclear [muscle] of
0.52. For the 3 other antibiotics in Table 3, no significant
improvement in the fit was obtained by the addition of an
fclear, suggesting that they are flow limited. This is con-
sistent with eq. (6) since these antibiotics have an fP of
0.38 or greater and should have an fclear of greater than
0.7 (assuming a PS = 7, the value obtained for
flucloxacillin).
The PBPK estimates of PS of muscle for the β-lactam anti-
biotics PS are 11.3 ml/min/100 g for dicloxacillin, 7 for
flucloxacillin and 5 for ceforanide. Since these three
antibiotics have similar structures, one would expect them
to have similar PS values. This suggests that the difference
in these three PS values provides an indication of the
uncertainty in the approach of using PBPK fitting to deter-
mine PS. These values are somewhat larger than the recent
estimate of Watson [55] for cat skeletal muscle PS of 5 and
7.6 ml/min/100 g for EDTA and mannitol, respectively.
These values of Watson [55] were obtained at very high
isoproterenol induced blood flows (more than 10 times
resting flows) and one would expect these PS values
should be greater than the resting PBPK values because of
the recruitment of new capillaries and the accompanying
increase in capillary surface area. The PBPK value esti-
mated in this paper for the PS of inulin in skeletal muscle
is 0.61 ml/min/100 g (see fig. 6) which is in the range of
values reported in the literature (0.59 to 1.62 [25]).
The capillary permeability measurements reported here
using the PBPK approach are limited by fact that they are
whole animal studies. The pharmacokinetics for these
extracellular solutes and, therefore, the capillary permea-
bility estimates, are dominated by the organs "skin", "ten-
don" and "other" which represent 62% of the
extravascular water (Table 6). In the implementation in
PKQuest, the parameter fclear [muscle] is input, and the
fclear of all the other organs are then determined using eq.
(6) and a preprogrammed value of PS of each organ rela-
tive to muscle. It has been assumed in PKQuest that
"skin", "tendon" and "other" have the same PS as skeletal
muscle (see Methods).
Despite the quantitative uncertainty in these PS measure-
ments, the qualitative implications are clear. For solutes
such as EDTA, mannitol, morphine-6-glucluronide and
the weakly bound β-lactam antibiotics, adding the addi-
tional factor of a capillary permeability limitation does
not significantly improve the fit between the experimental
data and the PBPK model prediction. That is, a flow-lim-
ited model adequately describes these solutes. In contrast,
as predicted using eq. (6), a capillary permeability limita-
tion significantly improves the fit for the highly protein
bound β-lactam antibiotics.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/3
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Conclusions
In general, each solute that is modeled by PBPK requires
unique information about the binding or partition in the
individual organs – information that can only by
obtained by measurements in animals and then extrapo-
lated to humans. However, this step is not necessary for
the extracellular solutes investigated here. Since the sol-
utes do not enter cells, all the diverse cellular binding and
uptake processes are circumvented. In addition, if the
interstitial binding is primarily due to albumin, as in the
case of the β-lactam antibiotics, then the interstitial bind-
ing can be predicted just from information about the
interstitial albumin concentration (KA, Table 6). Thus,
one can develop a PBPK model or parameter set (Table 6)
that is generally applicable to this class of drugs.
This approach is illustrated here for the 11 solutes listed in
Tables 1 and 3. A comparison of the model predictions
with the experimental data is shown in figs.
2,3,4,5,6,7,8,9,10,11,12. The same PBPK parameter set
(Table 6) was used for all of the solutes. The PBPK model
predictions shown in these figures were based on the use
of only 1 (renal clearance) or 2 (skeletal muscle PS for
drugs with high binding) adjustable parameters. In prin-
cipal, the PS can also be predicted using eq. (6) if an accu-
rate value of fP  is available. Thus, if one knows the
systemic clearance for these extracellular solutes, it should
be possible to predict the complete time course of the
absolute drug concentrations in all the major organs.
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Appendix
I. Volume of distribution of 2-compartment model for case 
where clearance is slow compared to compartment 
exchange
A two compartment system with a clearance rate constant
of k10 from the central compartment and exchanges rates
of k12 and k21 between the central and peripheral compart-
ments has the following kinetic solution for the central
(venous) concentration c(t) in response to a unit bolus
input (V1 is the volume of the central compartment, D is
the bolus dose):
For the special case where the clearance rate constant is
small compared to the other exchange rates (k10 << k12 +
k21):
One can define an "equilibrium volume of distribution"
(Veq) for the case where the clearance rate constant (k10) is
set to zero and the exchange between the peripheral and
central compartment is in equilibrium (A1 and A2 are the
amounts in the two compartments):
Substituting this relation for Veq into eq. (A.12) for B2:
(A.14)   Veq  D / B2
This expression for Veq is identical to volume of distribu-
tion that Wagner [11] defined as Vdext:
(A.15)   Veq  Vdext = D / Bβ
where Bβ is the coefficient of the slow, terminal exponen-
tial, determined by extrapolating the terminal component
back to time 0, and Vdext is the "extrapolated volume of
distribution".
II. Derivation of expression for steady state volume of 
distribution for the case of blood and tissue albumin 
binding
Definitions:
VD Steady state volume of distribution
VP Plasma volume
VE Interstitial space for EDTA.
Vi Interstitial space for solute i.
λE, λi Fraction of VE and Vi that albumin distributes in (λ ≤
1).
αi = Vi/VE (αi ≥ λE).
CP Total (free + bound) solute concentration in plasma.
cP, c Free concentration in plasma and tissue.
fP, fi, f0 Fraction of total solute that is free in plasma and
tissue and at 0 concentration.
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k Albumin binding constant for solute i.
BP Concentration of protein binding sites in plasma.
BI Concentration of protein binding sites in interstitial
protein space.
β = BI/BP.
KA = βλE
The steady state volume of distribution of solute i (VD) is
define by:
(A.16)   Amount = VDCP = VPCP + V1C1 + V2C2
where Amount is the total amount of solute in the organ,
CP,C1 and C2 are the total (free plus bound) solute concen-
tration in plasma space VP, in the interstitial space V1 that
albumin distributes in and in the remainder of the
interstitial space V2 available to the solute but not to albu-
min. Using the above definitions of λi, V1 and V2 can be
related to the interstitial space of solute i (Vi):
(A.17)   V1 = λiVi   V2 = (1 - λi) Vi
Since the total concentration C is related to the free con-
centration c by C = c/f, and at steady state, c has the same
value in all three compartments (assuming removal only
from the plasma compartment):
where fp and fi are the fraction of total solute that is free in
the plasma and interstitial space, respectively, and it has
been assumed there is no protein binding in V2. Solving
(A.18) for VD:
The fraction free (f) is related to the protein binding con-
stant (k) and the concentration of protein binding sites
(B) by the Scatchard equation:
For the case of linear protein binding (no saturation), kc
<< 1 and δ (eq. (A.19)) is equal to:
(A.21)   δ = fp (1 + λkBI)   (Linear)
where BI is the interstitial protein concentration. For the
linear case, the binding constant k in eq. (A.21) can be
expressed in terms of fp  and Bp  (plasma protein
concentration):
(A.22)   δ = βλi + fP (1 - βλi)   (Linear)
where β is the ratio BI/Bp. Finally, since the parameters λi
and Vi depend on the specific solute, they need to be
related to some standard value. In PKQuest, the standard
is EDTA (λE, VE):
Also, it is assumed that Vi ≥ Valb, and, therefore, αi ≥ λE.
Substituting these relations into eqs. (A.22) and (A.19) :
(A.24)   VD = VP + VE [βλE + fp (αi - βλE)]   (Linear)
The interstitial volume of distribution of the bound solute
VI (= VD-VP) can then be expressed relative to VE, the inter-
stitial volume of the EDTA (assumed to have no protein
binding):
(A.25)   VI / VE = (αi - KA) fp + KA   KA = βλE
where KA is the albumin concentration in the EDTA inter-
stitial space divided by the plasma albumin
concentration.
III. Modification of differential equations describing PBPK 
model if the interstitial protein volume is less than the 
interstitial volume of solute i
In the original derivation for PKQuest [7], it was assumed
that the solute and the protein (albumin) distributed in
the same interstitial volume. If the protein volume is less
than the solute volume, then the differential equation
describing the change in total tissue solute concentration
(eq. 17 in [7]) must be modified. The total interstitial
amount (Ai) of solute i is described by the second two
terms on the right side of eq. (A.18):
where ci and cb are the free and bound tissue concentra-
tions of solute i and eq. (A.20) has been substituted for fi.
Comparing the expression for cb in eq. (A.26) with the
original expression (eq. 16 in [7]), it can be seen that the
only modification that is required is the substitution of
λiBI in place of BI.
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In the implementation in PKQuest the interstitial binding
in organ j is characterized by the following set of
parameters:
ecf [j]: interstitial EDTA volume as fraction of total organ
water.
frecf [j,i]: = αi = interstitial space of solute i as fraction of
EDTA space
cProt [j]: = KA
j = βλE
λiBI = cProt*Bp /frecf
Additional material
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